MRI-Guided Interventions in Musculoskeletal System.

Image-guided interventions in the musculoskeletal system require accurate detection and characterization of lesions involving bone and soft tissues. Magnetic resonance imaging (MRI) has superior soft tissue contrast resolution particularly in bone and soft tissues where computed tomography and ultrasonography have significant limitations. In addition, the multiplanar imaging capabilities of MRI facilitate targeting lesions and tracking interventional devices. Although conventional diagnostic MRI sequences suffer from motion sensitivity and prolonged imaging time, recently developed fast imaging sequences allow for rapid acquisition of high-quality images, rendering MRI more suitable for image-guided interventions. Although computed tomography and ultrasonography still dominate the spectrum of image-guided interventions in the musculoskeletal system, many MRI-guided procedures have been developed and are well established in routine clinical work. In addition, new techniques and novel MRI-guided applications are being developed to address complex clinical problems in a minimally invasive fashion.

Efficacy of a Self-expanding Tract Sealant Device in the Reduction of Pneumothorax and Chest Tube Placement Rates After Percutaneous Lung Biopsy: A Matched Controlled Study Using Propensity Score Analysis.

PURPOSE: To evaluate the use of a self-expanding tract sealant device (BioSentry™) on the rates of pneumothorax and chest tube insertion after percutaneous lung biopsy. MATERIALS AND METHODS: In this retrospective study, we compared 318 patients who received BioSentry™ during percutaneous lung biopsy (treated group) with 1956 patients who did not (control group). Patient-, lesion-, and procedure-specific variables, and pneumothorax and chest tube insertion rates were recorded. To adjust for potential selection bias, patients in the treated group were matched 1:1 to patients in the control group using propensity score matching based on the above-mentioned variables. Patients were considered a match if the absolute difference in their propensity scores was ≤equal to 0.02. RESULTS: Before matching, the pneumothorax and chest tube rates were 24.5 and 13.1% in the control group, and 21.1 and 8.5% in the treated group, respectively. Using propensity scores, a match was found for 317 patients in the treatment group. Chi-square contingency matched pair analysis showed the treated group had significantly lower pneumothorax (20.8 vs. 32.8%; p = 0.001) and chest tube (8.2 vs. 20.8%; p < 0.0001) rates compared to the control group. Sub-analysis including only faculty who had >30 cases of both treatment and control cases demonstrated similar findings: the treated group had significantly lower pneumothorax (17.6 vs. 30.2%; p = 0.002) and chest tube (7.2 vs. 18%; p = 0.001) rates. CONCLUSIONS: The self-expanding tract sealant device significantly reduced the pneumothorax rate, and more importantly, the chest tube placement rate after percutaneous lung biopsy.

Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T.

OBJECTIVES: Real-time magnetic resonance imaging (MRI)-guided cryoablation has been investigated in open MRI systems with low magnetic fields (0.2-0.5 T). More advanced imaging techniques and faster imaging rates are possible at higher magnetic fields, which often require a closed-bore magnet design. However, there is very little experience with real-time interventions in closed-bore 1.5-T MRI units. Herein, we report our initial experience with real-time MRI-guided cryoablation of small renal tumors using a prototype balanced steady-state free precession imaging sequence in a closed-bore 1.5-T MRI system. MATERIALS AND METHODS: From August 2008 to April 2012, 18 patients underwent MRI-guided cryoablation of small renal tumors. A 1.5-T cylindrical MRI scanner with a 125 cm × 70 cm bore and a prototype balanced steady-state free precession sequence (BEAT interactive real-time tip tracking) were used to guide the placement of 17-gauge cryoprobes in real time. Ice ball formation was monitored every 3 minutes in 1 or more imaging planes. Each ablation consisted of 2 freeze-thaw cycles. Contrast-enhanced MRI was performed after the second active thaw period. Follow-up consisted of clinical evaluation and renal protocol computed tomography (CT) or MRI performed at 1, 6, 12, 18, and 24 months and annually thereafter. RESULTS: During the study period, we successfully ablated 18 tumors in 18 patients in 18 sessions. The mean tumor size was 2.2 cm (median, 2 cm; range, 1.2-4.4 cm). The number of cryoprobes used per patient was determined based on tumor size. The mean number of cryoprobes used per patient was 3 (median, 3 cryoprobes; range, 2-4 cryoprobes). Fifty-six cryoprobes, 9 biopsy needles, and 2 hydrodissection needles were successfully placed under real-time MRI guidance using BEAT interactive real-time tip tracking sequence. Hydrodissection under MRI guidance was successfully performed in 4 patients. In each patient, contrast-enhanced MRI performed after the second active thaw period revealed a sharply defined avascular zone surrounding the targeted tumor, which confirmed complete ablation of the tumor with adequate margins. Although contrast media slowly accumulated in the targeted tumor in 9 patients immediately after the procedure, follow-up imaging studies performed at a mean of 16.7 months revealed no contrast enhancement within the ablation zone in these patients. Disease-specific, metastasis-free, and local recurrence-free survival rates were all 100%. CONCLUSIONS: Real-time placement and manipulation of cryoprobes during MRI-guided cryoablation of small renal tumors in a closed-bore, high-magnetic field scanner are feasible. Technical and clinical success rates are similar to those of patients who undergo CT-guided radiofrequency ablation or cryoablation of small renal tumors. Our findings suggest that MRI-guided ablation has several advantages over CT-guided ablation, including real-time guidance for probe placement, multiplanar imaging, exquisite soft tissue contrast, and lack of ionizing radiation.

Magnetic resonance imaging-guided biopsy in the musculoskeletal system using a cylindrical 1.5-T magnetic resonance imaging unit.

OBJECTIVES: The objective of this study was to report a single-center experience with magnetic resonance imaging (MRI)-guided biopsy in the musculoskeletal system using a closed-bore, cylindrical, high-magnetic-field (1.5-T) MRI unit. METHODS: From May 2010 to July 2011, 100 consecutive MRI-guided biopsy sessions were undertaken for musculoskeletal lesions in 97 patients. Patient demographics, tumor characteristics, and biopsy techniques were recorded. Biopsy results, treatment outcomes, and follow-up imaging studies were reviewed. RESULTS: Biopsy procedures were technically successful in 99 cases (99%). Despite a mean body mass index of 30 kg/m, all patients fit within the bore of the magnet. There were 69 soft-tissue and 31 bone tumors. Most patients had both tissue core (n = 93) and fine-needle aspiration (n = 84) biopsies. All lesions were adequately imaged, localized, and targeted using rapid balanced steady-state free precession imaging (89%), fast T1 (4%), or combination of the 2 techniques (7%). A prototype real-time imaging sequence was used in 29 cases (29%) to guide biopsy needle insertion. There were no major complications. Sensitivity, specificity, and overall accuracy were 97%, 100%, and 97.6%, respectively. CONCLUSIONS: Magnetic resonance imaging-guided biopsy in a closed-bore, high-field-strength magnet is a safe, easy, and effective technique for evaluation of musculoskeletal lesions. Ideally, the MRI suite should be equipped with an in-room radiofrequency-shielded monitor and a communication system. However, surface coils with adequate opening to grant access to the biopsy site, MRI-compatible needles, and MRI-compatible patient monitoring devices are absolutely necessary to perform MRI-guided biopsies.

Characterization of contrast enhancement in the ablation zone immediately after radiofrequency ablation of renal tumors.

PURPOSE: To characterize the degree of contrast enhancement within the ablation zone immediately after radiofrequency (RF) ablation of renal tumors. MATERIALS AND METHODS: Patients with renal tumors treated with percutaneous RF ablation at one institution between January 2004 and October 2007 were retrospectively reviewed. For each tumor, computed tomography (CT) density measurements were made at four phases (noncontrast, arterial phase, parenchymal phase, and excretory phase) in each of four CT examinations (before ablation, day 0, 1 month, and 6 months). RESULTS: A total of 36 renal tumors in 34 patients were treated with CT-guided RF ablation in 35 sessions. Before RF ablation, all tumors exhibited enhancement after intravenous administration of contrast material. The peak density was reached during the parenchymal phase, with a partial washout of contrast agent in the excretory phase. On CT images acquired immediately after RF ablation (day 0), 28 of the 36 ablated tumors (78%) exhibited clinically significant homogeneous enhancement (ie, density change >10 HU) within the ablation zone. However, contrast-enhanced CT studies performed at 1 and 6 months revealed no clinically significant enhancements in any of the 36 treated tumors (mean density changes of 4 HU at 1 month and 3 HU at 6 months). CONCLUSIONS: Contrast-enhanced CT studies revealed a mild, temporary homogenous contrast enhancement of the ablation zone immediately after RF ablation of renal tumors, which should not be mistaken for a residual, unablated tumor. This enhancement in the ablation zone eventually disappears in follow-up contrast-enhanced CT studies.

Preclinical assessment of a 980-nm diode laser ablation system in a large animal tumor model.

PURPOSE: To characterize the performance of a 980-nm diode laser ablation system in an in vivo tumor model. MATERIALS AND METHODS: This study was approved by the institutional animal care and use committee. The ablation system consisted of a 15-W, 980-nm diode laser, flexible diffusing-tipped fiber optic, and 17-gauge internally cooled catheter. Ten immunosuppressed dogs were inoculated subcutaneously with canine-transmissible venereal tumor fragments in eight dorsal locations. Laser ablations were performed at 79 sites where inoculations were successful (99%) at powers of 10 W, 12.5 W, and 15 W, with exposure times between 60 and 180 seconds. In 20 cases, multiple overlapping ablations were performed. After the dogs were euthanized, the tumors were harvested, sectioned along the applicator tract, measured, and photographed. Measurements of ablation zone were performed on gross specimen. Histopathology and viability staining was performed with hematoxylin and eosin and nicotinamide adenine dinucleotide hydrogen staining. RESULTS: Gross pathologic examination confirmed a well circumscribed ablation zone with sharp boundaries between thermally ablated tumor in the center surrounded by viable tumor tissue. When a single applicator was used, the greatest ablation diameters ranged from 12 mm at the lowest dose (10 W, 60 seconds) to 26 mm at the highest dose (15 W, 180 seconds). Multiple applicators created ablation zones as large as 42 mm in greatest diameter (with the lasers operating at 15 W for 120 seconds). CONCLUSIONS: The new 980-nm diode laser and internally cooled applicator effectively create large ellipsoid thermal ablations in less than 3 minutes.